Adaptive Protocol Design
Development of an adaptive protocol for a complex oncology trial with multiple treatment arms.
Client
Mid-size Oncology Biotech
Therapeutic Area
Oncology - Precision Medicine
Document Type
Clinical Trial Protocol
Result
Efficient trial advancement with robust interim analyses
The Challenge
Our client, a mid-size oncology biotech company, was developing a novel targeted therapy with potential efficacy across multiple cancer subtypes defined by specific biomarkers. They faced several significant challenges in designing an efficient clinical development program:
- Need to evaluate efficacy across five distinct biomarker-defined patient populations simultaneously
- Limited understanding of biomarker prevalence and potential response rates in each subgroup
- Ethical concerns about continuing enrollment in subgroups showing minimal efficacy
- Complex statistical considerations for multiple cohorts and decision points
- Need to maximize operational efficiency and minimize overall development timeline
The client initially considered running separate phase II trials for each biomarker subgroup, but this approach would have been prohibitively expensive and time-consuming, significantly delaying potential market access for patients who could benefit from the therapy.
Key Protocol Challenges
Statistical Framework
Designing robust statistical methodology for multiple cohorts with interim analyses
Decision Rules
Establishing clear criteria for cohort expansion, closure, or advancement
Regulatory Acceptance
Ensuring adaptive design would meet regulatory standards across regions
Operational Complexity
Managing complex enrollment, biomarker testing, and data monitoring procedures
Our Approach
EloquiMed implemented a comprehensive approach to develop an innovative adaptive trial protocol:
1. Master Protocol Framework Development
We designed a master protocol framework with multiple biomarker-specific cohorts that allowed for independent decision-making for each patient subgroup while maintaining statistical rigor. The protocol included a common screening platform, streamlined eligibility criteria, and standardized endpoints for efficient cross-cohort comparison.
2. Statistical Design Optimization
Our biostatisticians developed a Bayesian adaptive design with response-adaptive randomization, allowing for efficient evaluation across multiple cohorts simultaneously. The approach incorporated clear futility and efficacy boundaries, optimized sample sizes, and sophisticated interim analysis frameworks that maximized statistical power while minimizing patient exposure to potentially ineffective treatments.
3. Clear Decision Framework Implementation
We established transparent decision rules for cohort expansion, closure, and advancement to later development phases. These rules balanced statistical rigor with operational feasibility, providing investigators and sponsors with clear guidance at each interim analysis point while maintaining trial integrity and minimizing operational bias.
4. Regulatory Strategy Integration
Our protocol incorporated regulatory considerations from both FDA and EMA perspectives, with specific attention to recent guidance on master protocols and adaptive designs. We ensured all Informed Consent Forms were compliant with ICH-GCP, FDA, and EMA guidelines, clearly outlining trial procedures, patient rights, risks, and benefits. These were tailored for adaptive design complexities, ensuring participants understood potential changes in treatment or study arms, and included robust plans for data monitoring committee operations and independent statistical analysis.
5. Operational Feasibility Planning
We developed detailed operational procedures for biomarker testing, patient allocation, site management, and data review timelines. The protocol included comprehensive logistics for interim analyses, communication plans, and implementation strategies that balanced scientific rigor with real-world operational constraints to ensure smooth execution.
5
Biomarker Cohorts
3
Interim Analyses
40%
Timeline Reduction
Results & Impact
Regulatory Success
The protocol received positive feedback from both FDA and EMA, with regulators specifically commending the innovative design and clear decision frameworks. No major modifications were requested during regulatory review.
Efficient Resource Use
Early stopping rules allowed two ineffective biomarker cohorts to be closed after the first interim analysis, redirecting resources to promising cohorts and accelerating the development timeline by approximately 40%.
Clinical Impact
The trial identified two biomarker-defined populations with exceptional response rates, leading to breakthrough therapy designation for these indications and accelerated development paths for patients most likely to benefit.
"EloquiMed's expertise in adaptive protocol design transformed our clinical development strategy. What would have been five separate trials became an elegant, efficient master protocol that allowed us to rapidly identify the patient populations who most benefit from our therapy. Their ability to balance statistical rigor with operational feasibility was exceptional."
Key Documentation Delivered
Master Protocol
Comprehensive protocol document with detailed cohort-specific methodology and adaptive features
Informed Consent Forms
Comprehensive ICFs detailing study procedures, patient rights, risks, benefits, and handling of adaptive design elements.
Biomarker Analysis Plan
Framework for biomarker testing, data integration, and exploratory analyses
DMC Charter
Comprehensive data monitoring committee procedures for interim decision-making
Operational Manual
Detailed procedures for implementing adaptive features and managing cohort transitions
Regulatory Briefing Document
Strategic document for FDA and EMA discussions on adaptive design approach
Simulation Report
Comprehensive analysis of design operating characteristics under various scenarios
Clinical Development Plan
Strategic roadmap for advancing successful cohorts to registration trials
Protocol Development Timeline
Initial Assessment & Strategy Development
- Comprehensive evaluation of preclinical and available clinical data
- Biomarker strategy assessment and prevalence analysis
- Statistical design exploration and simulation planning
- Development of master protocol concept and framework
Design Optimization & Statistical Modeling
- Statistical simulation across multiple scenarios
- Development of detailed interim analysis framework
- Establishment of cohort-specific decision rules
- Optimization of sample sizes and analysis timing
Protocol Development & Cross-functional Alignment
- Drafting of complete master protocol document
- Development of biomarker testing strategy and procedures
- Cross-functional review with biostatistics, clinical, regulatory, and operations teams
- Refinement based on stakeholder feedback
Finalization & Regulatory Engagement
- Final protocol approval and supporting document package completion
- Regulatory briefing document preparation
- FDA and EMA pre-IND/scientific advice meetings
- Protocol refinement based on regulatory feedback
Related Case Studies
Need expert protocol development?
Partner with EloquiMed for innovative clinical trial protocol design and development. Our team specializes in adaptive designs that maximize efficiency and clinical insights while meeting regulatory requirements.